Literature DB >> 16504983

Orphan drugs revisited.

C McCabe1, A Tsuchiya, K Claxton, J Raftery.   

Abstract

Mesh：

Year:  2006        PMID： 16504983     DOI： 10.1093/qjmed/hcl033

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


× No keyword cloud information.
  11 in total

1.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  Access to orphan drugs despite poor quality of clinical evidence.

Authors:  Alain G Dupont; Philippe B Van Wilder
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

3.  Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67.

Authors:  Arna S Desser; Dorte Gyrd-Hansen; Jan Abel Olsen; Sverre Grepperud; Ivar Sønbø Kristiansen
Journal:  BMJ       Date:  2010-09-22

Review 4.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

Review 5.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

6.  Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Authors:  Laura Gutierrez; Julien Patris; Adam Hutchings; Warren Cowell
Journal:  Orphanet J Rare Dis       Date:  2015-05-03       Impact factor: 4.123

7.  Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients.

Authors:  Andrea Messori
Journal:  Sci Pharm       Date:  2016-01-24

8.  The (Ir)relevance of Group Size in Health Care Priority Setting: A Reply to Juth.

Authors:  Lars Sandman; Erik Gustavsson
Journal:  Health Care Anal       Date:  2017-03

9.  Clinical evidence for orphan medicinal products-a cause for concern?

Authors:  Eline Picavet; David Cassiman; Carla E Hollak; Johan A Maertens; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-10-16       Impact factor: 4.123

Review 10.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.